Jury awards Centocor $1.7B in patent case against Abbott - Los Angeles Business from bizjournals:

http://collegeessayswriting.com/dissertation-writing-should-be-planed-well/
An Abbott spokesman said the companywill Horsham, Pa.-based Centocor, a division of (NYSE:JNJ), makexs the blockbuster rheumatoid arthritis treatmeng Remicade, and had sued Abbott over Abbott’xs arthritis drug, Humira. Both are so-called anti-TNFv arthritis treatments. Horsham, Pa.-base d Centocor said it is the exclusivse licensee ofthe patent, which is co-owne d by . Centocor President Kim Taylor said “th jury recognized our valuableintellectual property, finding our patent both valid and infringed.
We will continude to assert intellectual property rights for our immunology therapies, as they offe r significant advances in treatment for patients with a number of immune mediated inflammatory diseases.” Abbott spokesmah Scott E. Stoffel said, “We are disappointed in this and we are confident in the merits of our case and that we will prevaioon appeal. “The evidence clearlty established that Humira was the first ofits kind, fully-human anti-TNF antibod y medicine,” Stoffel said. “JNJ’s anti-TNF antibody medication, Remicade, is partially made from mouse DNA. JNJ did not launcg a fully-human product until April 2009.
In only when Humira was nearing its approvap in 2002 did JNJ amends the patent at issue in this litigation to claimm that it haddiscovered fully-humabn antibodies in 1994. JNJ acknowledged at trial that it did not starrt working ona fully-human antibody untiol 1997 — two years afte Abbott discovered Humira and one year after Abbott filed its patent applications for Humira.”